HOUSE 1734118th CongressBecame Public Law No: 118-23.

TRANQ Research Act of 2023

Last Action: 12/19/2023

Actions

2023-12-19Became Public Law No: 118-23.
2023-12-19Became Public Law No: 118-23.
2023-12-19Signed by President.
2023-12-19Signed by President.
2023-12-14Presented to President.
2023-12-14Presented to President.
2023-12-04Motion to reconsider laid on the table Agreed to without objection.
2023-12-04On motion that the House suspend the rules and agree to the Senate amendment Agreed to by voice vote. (text: CR H6087-6088)
2023-12-04Resolving differences -- House actions: On motion that the House suspend the rules and agree to the Senate amendment Agreed to by voice vote. (text: CR H6087-6088)
2023-12-04DEBATE - The House proceeded with forty minutes of debate on the motion to suspend the rules and agree to the Senate amendment to H.R. 1734.
2023-12-04Mr. Lucas moved that the House suspend the rules and agree to the Senate amendment. (consideration: CR H6087-6089)
2023-06-26Message on Senate action sent to the House.
2023-06-22Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S2250-2251)
2023-06-22Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(text of amendment in the nature of a substitute: CR S2250-2251)
2023-06-22Measure laid before Senate by unanimous consent. (consideration: CR S2250)

Showing 15 of 20 actions. Full history on Congress.gov.

CRS Summary

As of 2023-12-19 (49)

Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023 or the TRANQ Research Act of 2023

This bill requires the National Institute of Standards and Technology (NIST) to support research and other activities related to identifying xylazine (a compound used in veterinary medicine as a nonopioid tranquilizer), novel synthetic opioids, and other new psychoactive substances.

In particular, NIST must support

basic measurement science and research;
near-real time spectrometry capabilities (i.e., a technique for rapidly identifying the chemical composition of a substance);
strategies and voluntary best practices for handling, transporting, and analyzing such substances; and
collaboration with other government agencies, institutions of higher education, and the private sector to enhance relevant narcotic and opioid detection and analysis capabilities.

Additionally, the Government Accountability Office must conduct a study on the capabilities of the federal government to detect, identify, and otherwise respond to threats of new psychoactive substances, such as xylazine.

Cosponsors (20)

Yadira Caraveo (D-CO)
FRANK LUCAS (R-OK)
ZOE LOFGREN (D-CA)
Eric Crawford (R-AR)
Valerie Foushee (D-NC)
Jay Obernolte (R-CA)
Jennifer McClellan (D-VA)
Thomas Kean (R-NJ)
Deborah Ross (D-NC)
Mike Garcia (R-CA)
Kevin Mullin (D-CA)
Claudia Tenney (R-NY)
Eric Sorensen (D-IL)
Brandon Williams (R-NY)
David Trone (D-MD)
Randy Weber (R-TX)
Brian Babin (R-TX)
Dale Strong (R-AL)
C. Franklin (R-FL)
Max Miller (R-OH)

Subjects

Advanced technology and technological innovations
Chemistry
Congressional oversight
Drug trafficking and controlled substances
Higher education
Research administration and funding
Science and engineering education

Became law: Pub. L. 118-23

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.